Literature DB >> 18413728

Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma.

Jan J Molenaar1, Marli E Ebus, Jan Koster, Peter van Sluis, Carel J M van Noesel, Rogier Versteeg, Huib N Caron.   

Abstract

Genomic aberrations of Cyclin D1 (CCND1), CDK4, and CDK6 in neuroblastoma indicate that dysregulation of the G(1) entry checkpoint is an important cell cycle aberration in this pediatric tumor. Here, we report that analysis of Affymetrix expression data of primary neuroblastic tumors shows an extensive overexpression of Cyclin D1, which correlates with histologic subgroups. Immunohistochemical analysis showed overexpression of Cyclin D1 in neuroblasts and low Cyclin D1 expression in all cell types in ganglioneuroma. This suggests an involvement of G(1)-regulating genes in neuronal differentiation processes which we further evaluated using RNA interference against Cyclin D1 and its kinase partners CDK4 and CDK6 in several neuroblastoma cell lines. The Cyclin D1 and CDK4 knockdown resulted in pRb pathway inhibition as shown by an almost complete disappearance of CDK4/CDK6-specific pRb phosphorylation, reduction of E2F transcriptional activity, and a decrease of Cyclin A protein levels. Phenotype analysis showed a significant reduction in cell proliferation, a G(1)-specific cell cycle arrest, and, moreover, an extensive neuronal differentiation. Affymetrix microarray profiling of small interfering RNA-treated cells revealed a shift in expression profile toward a neuronal phenotype. Several new potential downstream players are identified. We conclude that neuroblastoma functionally depend on overexpression of G(1)-regulating genes to maintain their undifferentiated phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413728     DOI: 10.1158/0008-5472.CAN-07-5032

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

1.  Temozolomide may induce cell cycle arrest by interacting with URG4/URGCP in SH-SY5Y neuroblastoma cells.

Authors:  Veli Çıtışlı; Yavuz Dodurga; Canan Eroğlu; Mücahit Seçme; Çığır Biray Avcı; N Lale Şatıroğlu-Tufan
Journal:  Tumour Biol       Date:  2015-04-03

2.  RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.

Authors:  Kristina A Cole; Jonathan Huggins; Michael Laquaglia; Chase E Hulderman; Mike R Russell; Kristopher Bosse; Sharon J Diskin; Edward F Attiyeh; Rachel Sennett; Geoffrey Norris; Marci Laudenslager; Andrew C Wood; Patrick A Mayes; Jayanti Jagannathan; Cynthia Winter; Yael P Mosse; John M Maris
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-02       Impact factor: 11.205

3.  Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome.

Authors:  Andrea Cornero; Massimo Acquaviva; Paolo Fardin; Rogier Versteeg; Alexander Schramm; Alessandra Eva; Maria Carla Bosco; Fabiola Blengio; Sara Barzaghi; Luigi Varesio
Journal:  BMC Bioinformatics       Date:  2012-03-28       Impact factor: 3.169

4.  CASZ1 inhibits cell cycle progression in neuroblastoma by restoring pRb activity.

Authors:  Zhihui Liu; Julieann Rader; Stanley He; Tanya Phung; Carol J Thiele
Journal:  Cell Cycle       Date:  2013-07-15       Impact factor: 4.534

5.  Hsa-miR-376c-3p targets Cyclin D1 and induces G1-cell cycle arrest in neuroblastoma cells.

Authors:  Swapnil Parashram Bhavsar; Cecilie Løkke; Trond Flægstad; Christer Einvik
Journal:  Oncol Lett       Date:  2018-09-11       Impact factor: 2.967

6.  Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma.

Authors:  Afak Rasheed Salman Zaidi; Sadie Dresman; Charlotte Burt; Simon Rule; Lynn McCallum
Journal:  J Cell Commun Signal       Date:  2018-11-21       Impact factor: 5.782

7.  Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.

Authors:  Julieann Rader; Mike R Russell; Lori S Hart; Michael S Nakazawa; Lili T Belcastro; Daniel Martinez; Yimei Li; Erica L Carpenter; Edward F Attiyeh; Sharon J Diskin; Sunkyu Kim; Sudha Parasuraman; Giordano Caponigro; Robert W Schnepp; Andrew C Wood; Bruce Pawel; Kristina A Cole; John M Maris
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

8.  Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells.

Authors:  Michele Navarra; Marilena Celano; Jessica Maiuolo; Silvia Schenone; Maurizio Botta; Adriano Angelucci; Placido Bramanti; Diego Russo
Journal:  BMC Cancer       Date:  2010-11-04       Impact factor: 4.430

9.  LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

Authors:  Jan J Molenaar; Raquel Domingo-Fernández; Marli E Ebus; Sven Lindner; Jan Koster; Ksenija Drabek; Pieter Mestdagh; Peter van Sluis; Linda J Valentijn; Johan van Nes; Marloes Broekmans; Franciska Haneveld; Richard Volckmann; Isabella Bray; Lukas Heukamp; Annika Sprüssel; Theresa Thor; Kristina Kieckbusch; Ludger Klein-Hitpass; Matthias Fischer; Jo Vandesompele; Alexander Schramm; Max M van Noesel; Luigi Varesio; Frank Speleman; Angelika Eggert; Raymond L Stallings; Huib N Caron; Rogier Versteeg; Johannes H Schulte
Journal:  Nat Genet       Date:  2012-10-07       Impact factor: 38.330

Review 10.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Authors:  Nai-Kong V Cheung; Michael A Dyer
Journal:  Nat Rev Cancer       Date:  2013-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.